Some of the collaborative projects within the network
COST Action: CardioRNA
Catalyzing transcriptomics research in cardiovascular disease
The COST Action CardioRNA (CA17129) will start in the second semester of 2018. It has as main goal to accelerate the understanding of transcriptomics in cardiovascular disease and further the translation of experimental data into practical applications for diagnostics and therapies to improve personalized medicine.
Along with the main proposers, Cardiolinc Board Members Yvan Devaux and Clarissa Pedrosa da C. Gomes, the Action was proposed by Cardiolinc members, partners and outside collaborators from Australia, Czech Republic, Denmark, France, Germany, Hungary, Italy, Luxembourg, Netherlands, Poland, Spain, Switzerland, Turkey and UK.
If you are interested in participating, please contact us.
Follow this link to the news about the acceptance for funding of CardioRNA and more details.
COST Action: CARDIOPROTECTION
Realising the therapeutic potential of novel cardioprotective therapies
Launched in July 2017, this Action aims improve the translation of novel cardioprotective therapies for patient benefit. It has four main objectives, each linked to a working group (WG):
WG1: New targets – use innovative strategies to discover novel targets for cardioprotection
WG2: Combination therapy – investigate the effects of combination therapy directed to multiple targets as an innovative cardioprotective strategy
WG3: Confounders – use more clinically relevant animal models for testing novel cardioprotective therapies taking into account the confounding effects of co-morbidities and co-medication
WG4: Consortium – set up a European network of research centers for:
(a) Multi-center preclinical testing of novel cardioprotective therapies using small/large animal models of acute myocardial ischaemia/reperfusion injury;
(b) Proof-of-concept clinical testing of novel cardioprotective therapies in acute myocardial patients
Cardiolinc members participating in the Action are Derek Hausenloy (Chair of the Action), Péter Ferdinandy (Vice Chair of the Action), David Erlinge, Monika Barteková, Przemyslaw Leszek, and Yvan Devaux.
Cardiolinc members Firalis, Hannover Medical School and Luxembourg Institute of Health, together with the LifeSequencing company, secured funding through the Eurostars program for a 3-year project aiming at developing an in vitro diagnostic assay for prognostication of patients with acute myocardial infarction.